Guilong Zhao Selected Research

1- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 1,6- dideoxyglucopyranose

5/2014

Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guilong Zhao Research Topics

Disease

2	Type 2 Diabetes Mellitus (MODY) 01/2015 - 05/2014
1	Postherpetic Neuralgia 01/2022
1	Fibromyalgia (Fibrositis) 01/2022
1	Neuralgia (Stump Neuralgia) 01/2022
1	Hyperuricemia 01/2017
1	Gout 01/2017

Drug/Important Bio-Agent (IBA)

2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2015 - 05/2014
1	LigandsIBA 01/2022
1	Calcium Channels (Calcium Channel)IBA 01/2022
1	AcidsIBA 01/2017
1	Uric Acid (Urate)IBA 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 05/2014
1	SodiumIBA 05/2014
1	1- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 1,6- dideoxyglucopyranoseIBA 05/2014